BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT06698887
- Locations
- 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun, Jeonranamdo, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 413
- Registration Number
- NCT06697197
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸Local Institution - 0005, Irvine, California, United States
🇺🇸Local Institution - 0030, Los Angeles, California, United States
A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
- Conditions
- Advanced Solid Tumors With Homozygous MTAP Deletion
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 8
- Registration Number
- NCT06672523
- Locations
- 🇭🇺
ICON / PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, Hungary
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Conditions
- Extensive-Stage Small Cell Lung Cancer
- Interventions
- Biological: BMS-986489 (BMS-986012+Nivolumab)
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 530
- Registration Number
- NCT06646276
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 198
- Registration Number
- NCT06618287
- Locations
- 🇺🇸
Local Institution - 0066, Birmingham, Alabama, United States
🇺🇸Local Institution - 0065, Iowa City, Iowa, United States
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
A Real-World Study of Β-Thalassemia Major Treatment with Luspatercept in Taiwan
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 61
- Registration Number
- NCT06596642
- Locations
- 🇨🇳
Local Institution - 02, Kaohsiung, Taiwan
🇨🇳Local Institution - 04, Tainan, Taiwan
🇨🇳Local Institution - 01, Taipei, Taiwan
A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 86
- Registration Number
- NCT06581055
- Locations
- 🇨🇳
National Taiwan University Hospital (NTUH), Taipei, Taiwan
Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT06577259
- Locations
- 🇺🇸
Local Institution - 0001, San Antonio, Texas, United States
A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 71
- Registration Number
- NCT06568458
- Locations
- 🇺🇸
Local Institution - 0001, Lenexa, Kansas, United States
Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 112
- Registration Number
- NCT06565975
- Locations
- 🇫🇷
Kappa Sante, Paris, France